IP Library Granted Patent US 7,811,595
Granted Patent B2
US 7,811,595 · App. 11/821,936 · Granted Oct 12, 2010

Prolyl hydroxylase inhibitors and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,811,595
App. No.
11/821,936
Granted
Oct 12, 2010
Kind
B2
Abstract

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Claims (184)

1. A compound having the formula:

wherein

R and R 1 are each independently:

i) hydrogen;

ii) substituted or unsubstituted phenyl; or

iii) substituted or unsubstituted heteroaryl;

said substitutions being:

i) C 1 -C 4 linear, branched, or cyclic alkyl;

ii) C 1 -C 4 linear, branched, or cyclic alkoxy;

iii) C 1 -C 4 linear, branched, or cyclic haloalkyl;

iv) halogen;

v) —CN;

vi) —NHC(O)R 4

vii) —C(O)NR 5a R 5b ; or

viii) heteroaryl; or

ix) two substitutions are taken together to form a fused ring having from 5 to 7 atoms;

R 4 is C 1 -C 4 linear, branched, or cyclic alkyl;

R 5a and R 5b are each independently:

i) hydrogen;

ii) C 1 -C 4 linear, branched, or cyclic alkyl; or

iii) R 5a and R 5b are taken together to form a ring having from 3 to 7 atoms;

R 2 is:

i) —OR 6 ; or

ii) —NR 7a R 7b ;

R 6 is hydrogen or C 1 -C 4 linear, branched, or cyclic alkyl;

R 7a and R 7b are each independently:

i) hydrogen; or

ii) C 1 -C 4 linear, branched, or cyclic alkyl; or

iii) R 7a and R 7b are taken together to form a ring having from 3 to 7 ring atoms;

R 3 is hydrogen, methyl, or ethyl;

L is a linking unit having the formula:

—[C(R 8a R 8b )] n —

R 8a and R 8b are each independently hydrogen, methyl, or ethyl;

the index n is from 1 to 3; and

R 9 is hydrogen or methyl;

or a pharmaceutically acceptable salt thereof;

provided R and R 1 are not both hydrogen.

2. A compound according to claim 1 , wherein R is substituted or unsubstituted phenyl.

3. A compound according to claim 1 , wherein R is chosen from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, and 4-chlorophenyl.

4. A compound according to claim 1 , wherein R is chosen from 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-iso-propoxyphenyl, 3-iso-propoxyphenyl, 4-iso-propoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, and 4-cyanophenyl.

5. A compound according to claim 1 , wherein R 1 is chosen from 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-iso-propoxyphenyl, 3-iso-propoxyphenyl, 4-iso-propoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, and 4-cyanophenyl.

6. A compound according to claim 1 , wherein R is a unit having the formula:

wherein R 10 has the formula —C(O)NR 5a R 5b ; R 5a and R 5b are each hydrogen or R 5a and R 5b are taken together to from a ring having 5 or 6 atoms.

7. A compound according to claim 1 , wherein R 5a and R 5b are taken together to form a pyrrolidin-1-yl ring.

8. A compound according to claim 1 , wherein R is a unit having the formula:

wherein R 10 has the formula —NHC(O)R 4 ; R 4 is a unit chosen from methyl, ethyl, n-propyl, iso-propyl, and cyclopropyl.

9. A compound according to claim 1 , wherein R is a unit having the formula:

wherein R 10 is a heteroaryl unit chosen from 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, and thiophene-3-yl.

10. A compound according to claim 1 , wherein R is substituted or unsubstituted heteroaryl.

11. A compound according to claim 1 , wherein R is a unit chosen from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, and isoquinolin-4-yl.

12. A compound according to claim 1 , wherein R is a unit chosen from thiazol-2-yl, thiazol-4-yl, 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, and thiophene-3-yl.

13. A compound according to claim 1 , wherein R 2 is —OR 6 ; R 6 is hydrogen or methyl.

14. A compound according to claim 1 , wherein R 6 is hydrogen.

15. A compound according to claim 1 , wherein R 6 is methyl.

16. A compound according to claim 1 , wherein R 2 is —NR 7a R 7b ; R 7a and R 7b are each independently hydrogen, methyl, or ethyl.

17. A compound according to claim 1 , wherein R 2 is chosen from:

i) —NH 2 ;

ii) —NHCH 3 ; or

iii) —N(CH 3 ) 2 .

18. A compound according to claim 1 , wherein R 3 is methyl.

19. A compound according to claim 1 , wherein R 3 is hydrogen.

20. A compound according to claim 1 , wherein L has the formula chosen from:

i) —CH 2 —;

ii) —CH 2 CH 2 —; or

iii) —C(CH 3 ) 2 —.

21. A compound according to claim 1 , wherein L has the formula —CH 2 —.

22. A compound according to claim 1 , having the formula:

wherein R is substituted or unsubstituted phenyl;

said substitutions are chosen from:

i) C 1 -C 4 linear, branched, or cyclic alkyl;

ii) C 1 -C 4 linear, branched, or cyclic alkoxy;

iii) C 1 -C 4 linear, branched, or cyclic haloalkyl;

iv) halogen;

v) —CN;

vi) —NHC(O)R 4

vii) —C(O)NR 5a R 5b ;

viii) heteroaryl; or

ix) two substitutions can be taken together to form a fused ring having from 5 to 7 atoms;

R 4 is C 1 -C 4 linear, branched, or cyclic alkyl;

R 5a and R 5b are each independently:

i) hydrogen;

ii) C 1 -C 4 linear, branched, or cyclic alkyl; or

iii) R 5a and R 5b can be taken together to form a ring having from 3 to 7 atoms.

23. A compound according to claim 1 , having the formula:

wherein R is a heteroaryl unit chosen from thiazol-2-yl, thiazol-4-yl, 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, and isoquinolin-4-yl.

24. A compound according to claim 1 , having the formula:

wherein R is substituted or unsubstituted phenyl;

said substitutions are chosen from:

i) C 1 -C 4 linear, branched, or cyclic alkyl;

ii) C 1 -C 4 linear, branched, or cyclic alkoxy;

iii) C 1 -C 4 linear, branched, or cyclic haloalkyl;

iv) halogen;

v) —CN;

vi) —NHC(O)R 4

vii) —C(O)NR 5a R 5b ;

viii) heteroaryl; or

ix) two substitutions can be taken together to form a fused ring having from 5 to 7 atoms;

R 4 is C 1 -C 4 linear, branched, or cyclic alkyl;

R 5a and R 5b are each independently:

i) hydrogen;

ii) C 1 -C 4 linear, branched, or cyclic alkyl; or

iii) R 5a and R 5b can be taken together to form a ring having from 3 to 7 atoms.

25. A compound according to claim 1 , having the formula:

wherein R is a heteroaryl unit chosen from thiazol-2-yl, thiazol-4-yl, 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, and isoquinolin-4-yl.

26. A compound chosen from:

{[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

{[5-(4-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

{[5-(2-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

{[5-(4-Fluoro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

[(3-Hydroxy-5-(4-methylphenyl)-pyridine-2-carbonyl)-amino]-acetic acid methyl ester;

{[3-Hydroxy-5-(4-isopropyl-phenyl)-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

{[5-(4-Ethyl-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

{[3-Hydroxy-5-(3-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

{[5-(4-Cyano-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

{[5-(3-Cyano-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

{[5-(3-Carbamoyl-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;

({3-Hydroxy-5-[3-(pyrrolidine-1-carbonyl)-phenyl]-pyridine-2-carbonyl}-amino)-acetic acid methyl ester;

({5-[3-(Cyclopropanecarbonyl-amino)-phenyl]-3-hydroxy-pyridine-2-carbonyl}-amino)-acetic acid methyl ester;

({3-Hydroxy-5-[3-(2H-tetrazol-5-yl)-phenyl]-pyridine-2-carbonyl}-amino)-acetic acid methyl ester;

[(5-Hydroxy-[3,3′]bipyridinyl-6-carbonyl)-amino]-acetic acid methyl ester

[(5′-Hydroxy-[2,3′]bipyridinyl-6′-carbonyl)-amino]-acetic acid methyl ester;

[(3-Hydroxy-5-pyrimidin-5-yl-pyridine-2-carbonyl)-amino]-acetic acid methyl ester;

[(3-Hydroxy-5-isoquinolin-4-yl-pyridine-2-carbonyl)-amino]-acetic acid methyl ester;

[(3-Hydroxy-5-thiazol-2-yl-pyridine-2-carbonyl)-amino]-acetic acid methyl ester;

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;

{[5-(4-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;

{[5-(2-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;

[(3-Hydroxy-5-(4-methylphenyl)pyridine-2-carbonyl)amino]-acetic acid;

{[5-(4-Ethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;

{[3-Hydroxy-5-(4-isopropylphenyl)pyridine-2-carbonyl]amino}-acetic acid;

{[3-Hydroxy-5-(3-trifluoromethylphenyl)pyridine-2-carbonyl]amino}-acetic acid;

{[5-(4-Cyanophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;

{[5-(3-Cyanophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;

{[5-(5-Chloro-2-methylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;

{[3-Hydroxy-5-(4-isopropoxyphenyl)pyridine-2-carbonyl]amino}-acetic acid;

({5-[3-(Cyclopropanecarbonylamino)phenyl]-3-hydroxy-pyridine-2-carbonyl}-amino)-acetic acid;

({3-Hydroxy-5-[3-(pyrrolidine-1-carbonyl)phenyl]-pyridine-2-carbonyl}amino)-acetic acid;

({3-Hydroxy-5-[3-(2H-tetrazol-5-yl)phenyl]-pyridine-2-carbonyl}-amino)-acetic acid;

[(5′-Hydroxy-[2,3′]bipyridinyl-6′-carbonyl)-amino]-acetic acid;

[(5-Hydroxy-[3,3′]bipyridinyl-6-carbonyl)-amino]-acetic acid;

[(3-Hydroxy-5-pyrimidin-5-yl-pyridine-2-carbonyl)-amino]-acetic acid;

[(3-Hydroxy-5-isoquinolin-4-yl-pyridine-2-carbonyl)-amino]-acetic acid;

[(3-Hydroxy-5-thiazol-2-yl-pyridine-2-carbonyl)-amino]-acetic acid;

{[5-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid;

5-(Chlorophenyl)-N-(2-amino-2-oxo-1,1-dimethylethyl)-3-hydroxylpyridin-2-yl amide;

5-(Chlorophenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(Chlorophenyl)-N-(2-amino-2-oxo-1-methylethyl)-3-hydroxylpyridin-2-yl amide;

5-(4-Methylphenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

2-{[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-2-methyl-propionic acid methyl ester;

2-{[5-(3-Chlorophenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-2-methyl-propionic acid

3-[(3-Hydroxy-5-(4-methylphenyl)-pyridine-2-carbonyl)-amino]-propionic acid ethyl ester;

3-[(3-Hydroxy-5-(3-chlorophenyl)-pyridine-2-carbonyl)-amino]-propionic acid ethyl ester;

3-{[5-(3-Chlorophenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-propionic acid;

3-[(3-Hydroxy-5-(4-methylphenyl)-pyridine-2-carbonyl)-amino]-propionic acid;

5-(Chlorophenyl)-N-(3-amino-3-oxo-1,1-dimethylpropyl)-3-hydroxylpyridin-2-yl amide; and

5-(3-Chlorophenyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide; or

a pharmaceutically acceptable salt thereof.

27. A composition comprising:

A) one or more compounds according to claim 1 ; and

B) one or more excipients or carriers.

28. A compound according to claim 1 , wherein the compound is a pharmaceutically acceptable salt of either basic groups or acid groups.

29. A compound according to claim 1 , wherein the compounds are salts comprising anions chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate.

30. A compound according to claim 1 , wherein the compounds are salts comprising cations chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.

31. A compound according to claim 1 , having the formula:

wherein R is substituted or unsubstituted phenyl;

said substitutions are chosen from:

i) C 1 -C 4 linear, branched, or cyclic alkyl;

ii) C 1 -C 4 linear, branched, or cyclic alkoxy;

iii) C 1 -C 4 linear, branched, or cyclic haloalkyl;

iv) halogen;

v) —CN;

vi) —NHC(O)R 4

vii) —C(O)NR 5a R 5b ;

viii) heteroaryl; or

ix) two substitutions can be taken together to form a fused ring having from 5 to 7 atoms;

R 4 is C 1 -C 4 linear, branched, or cyclic alkyl;

R 5a and R 5b are each independently:

i) hydrogen;

ii) C 1 -C 4 linear, branched, or cyclic alkyl; or

iii) R 5a and R 5b can be taken together to form a ring having from 3 to 7 atoms.

32. A compound according to claim 1 , having the formula:

wherein R is a heteroaryl unit chosen from thiazol-2-yl, thiazol-4-yl, 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, and isoquinolin-4-yl.

Assignments (11)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 27445 FRAME: 100. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 17, 2024
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 067456/0592 →
SECURITY INTEREST Recorded Jan 29, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 066377/0654 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2011
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS INC.
Reel/Frame 027445/0100 →
PATENT RELEASE Recorded Dec 23, 2011
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 027443/0164 →
SECURITY AGREEMENT Recorded Mar 30, 2011
From: WARNER CHILCOTT COMPANY LLC
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026064/0607 →
RELEASE - REEL 023456, FRAME 0052 Recorded Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY LLC
Reel/Frame 026042/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2010
From: PROCTER & GAMBLE COMPANY, THE
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 023796/0417 →
SECURITY AGREEMENT Recorded Nov 2, 2009
From: WARNER CHILCOTT COMPANY, LLC
To: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 023456/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2009
From: WU, SHENGDE; WARSHAKOON, NAMAL C.; EVDOKIMOV, ARTEM G.; GREIS, KENNETH D.; BOYER, ANGELIQUE SUN
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 022254/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2007
From: KAWAMOTO, RICHARD MASARU
To: PROCTER & GAMBLE COMPANY, THE
Reel/Frame 019648/0644 →